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In a recent issue ofCell, Valastyan et al. demonstrate thatmiR-31 can regulatemultiple steps in themetastatic
cascade independent of confounding effects on primary tumor development. These data have potential to
provide biomarkers for prognosis and novel targets for intervention in this most lethal aspect of malignancy.The classic view of tumor progression
and metastasis is thought to involve the
gradual accumulation of genetic changes
and the formation of evermore aggressive
tumor cells. As the field learns more about
the processes of cancer initiation and
progression, these ideas are changing.
Clinical insights have suggested that me-
tastasis, the often lethal spread of cells
from a primary tumor to a distant site,
may occur early rather than late, as previ-
ously thought (Schmidt-Kittler et al., 2003;
Husemann et al., 2008; Podsypanina
et al., 2008). Additionally, we now appre-
ciate that epigenetic regulation (via alter-
ations in microRNAs, histone modifica-
tions, and DNA methylation), as well as
genetic changes, play a pivotal role in the
acquisition of tumorigenic and metastatic
properties (Lujambio et al., 2008; Dumont
et al., 2008). Finally, the step-by-step ac-
quisition of genetic or epigenetic changes
is not necessarily needed;multiple pheno-
types can be acquired with one altera-
tion. For instance, the sole upregulation
of cyclo-oxygenase 2 (COX-2) confers
multiple phenotypes important in tumori-
genesis such as increased proliferation,
invasion, and angiogenesis as well as
decreased apoptosis and immune surveil-
lance. Likewise, in a recent issue of Cell,
Valastyan et al. (2009) now report that
the alteration of one microRNA (miRNA)
modulates multiple targets and affects
multiple phenotypes such as motility,
invasion, and resistance to anoikis. These
growing insights are very significant. With
increasedunderstandingofwhenandhow
key tumorigenic properties are acquired,
the opportunity for prevention and tar-
geted therapy increases. The metastatic
cascade presents a prime example of
these points.
The mechanisms that control the
metastatic dissemination of tumor cellsremain poorly understood. In order to
successfully establish growth at a
secondary site, tumor cells must first
leave the primary tumor, intravasate into
the systemic circulation, survive within
the vasculature, extravasate into the
parenchyma of distant tissues, and finally,
persist long enough to allow colonization
at the secondary site. As noted above,
although this metastatic cascade has
long been thought to be a late event in
the evolution of breast cancer, there is
now accumulating evidence that tumor
cells candisseminate in the earliest stages
of transformation. Husemann et al. (2008)
have demonstrated that in the BALB-
NeuT and the PyMT mammary tumor
models, dissemination begins shortly
after expression of the oncogenic trans-
gene when there are no histologically
detectable signs of invasion. This is also
true in human disease, as disseminated
tumor cells can be observed in the bone
marrow of women with DCIS prior to any
signs of invasive disease. Consistent
with the early dissemination hypothesis,
some have also reported that dissemi-
nated cancer cells in the bone marrow of
breast cancer patients exhibit fewer alter-
ations than their matched primary tumors
(Schardt et al., 2005; Schmidt-Kittler et al.,
2003). In addition, when untransformed
mammary cells that have been engi-
neered to express inducible oncogenes
are injected into the circulation, they can
develop into metastatic pulmonary
lesions without the need to be trans-
formed at their primary site of mammary
glands (Podsypanina et al., 2008). Finally,
the acquisition of behaviors that facilitate
metastasis, such as epithelial to mesen-
chymal transition (EMT), can occur via
epigenetic mechanisms in human cells
prior tomalignant transformation (Dumont
et al., 2008).CanceBecause of their ability to coordinately
regulate multiple target genes and their
association with clinical outcome, as first
suggestedbyCroceandcolleagues, alter-
ations in the levels of miRNAs can play an
important role in the regulation of meta-
stasis. To gain a better understanding of
metastatic dissemination, Valastyan and
colleagues screened a panel of differen-
tially regulatedmiRNAsbased on informa-
tion from the literature and now provide
compelling evidence using human and
murine cell lines, murine models, and
assessment of clinical samples, that a
specific miRNA, miR-31, acts as a metas-
tasis suppressor and regulates multiple
steps of the metastatic cascade.
This miRNA is expressed in normal
breast cells, moderately reduced in non-
metastatic, breast cancer cell lines, and
nearly completely repressed in metastatic
breast cancer cell lines of bothmurine and
human origin as well as in breast cancer
patients with metastatic disease. When
examined in primary human tissues,
miR-31 also demonstrated an inverse
correlation with metastasis-free survival.
Re-expression of miR-31 in metastatic
breast cancer cells suppressed multiple
surrogates of metastasis such as motility,
invasion, and resistance to anoikis in vitro
and suppressed metastasis following or-
thotopic injection into the mammary fat
pads of mice in vivo. Notably, metastasis
in vivo was suppressed despite the fact
that miR-31-expressing breast cancer
cells formed larger, more proliferative
tumors. This is consistent with observa-
tions by Husemann et al. (2008), which
indicated that the number and genotype
of seeded tumor cells are not associated
with tumor size. The authors found that
the larger tumors formed by miR-31-ex-
pressing cells were well encapsulated
and, thus, less locally invasive, indicatingr Cell 16, July 7, 2009 ª2009 Elsevier Inc. 3
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Figure 1. miR-31 Is Expressed in Normal and Nonmetastatic Breast Cells
Loss of miR-31 leads to an increase in the expression of several target genes, including RhoA, radixin
(RDX), and integrin alpha 5 (ITGA5), all of which promote motility, invasion, and resistance to anoikis. Addi-
tional anti- or prometastatic miRNAs are boxed, and their known corresponding target genes are shown in
parentheses. Image adapted from Kang and Massague (2004) by Drs. P. Gascard and S. Roy.4 Cancer Cell 16, July 7, 2009 ª2009 Elsevier Inc.miR-31. The functional relevance of
RhoA was also confirmed in vivo where
its re-expression was found to partially
reverse miR-31-induced suppression of
metastasis. This substantiates earlier
findings that RhoA plays an important
role in mediating EMT, which is thought
to be critical in metastasis (Bhowmick
et al., 2001). However, the fact that re-
expression of RhoA alone could not
completely reverse the defects in metas-
tasis imposed by miR-31 highlights the
involvement of multiple genes in regu-
lating metastasis. Hence, targeting plei-
tropic factors such as miR-31 that can
modulate several genes involved at
multiple steps of the metastatic cascade
would likely be a more effective thera-
peutic strategy than targeting a single
gene. The ‘‘one hit, multiple targets’’
nature of miRNAs is indeed making them
attractive therapeutic targets.that miR-31 can exert its suppressive
effects in the earliest steps of the meta-
static cascade. In addition, by injecting
the miR-31-expressing cells directly into
the circulation to circumvent miR-31’s
effects on local invasion, the authors
found that it also exerted its suppressive
effects in later steps of the metastatic
cascade, impairing the ability of the cells
to survive and form secondary tumors in
the lung. Thus,miR-31 exerts its antimeta-
static effects atmultiple steps in themeta-
static cascade. These observations were
also supported in converse experiments
where inhibition of miR-31 via either anti-
sense oligonucleotides or a novel miRNA
sponge technique, rendered otherwise
nonmetastatic breast cancer cells meta-
static. Notably, inhibition of miR-31 also
increased the invasive capacity and anoi-
kis resistance of immortalized human
mammary epithelial cells. This suggests
that inactivation of miR-31 in normal
mammary epithelium may facilitate
dissemination prior to transformation to
a fully neoplastic state, consistent with
the aforementioned studies which now
demonstrate that metastatic spread can
be initiated early in the transformation
process.
Collectively, the authors provide con-
vincing data indicating that sustained
miR-31 activity is necessary to preventacquisition of aggressive traits by both
tumor cells and untransformed breast epi-
thelial cells. Importantly, unlike a number
ofmiRNAs thathavebeen reported tohave
prometastatic or antimetastatic functions
(Negrini and Calin, 2008), the authors
were able to demonstrate that miR-31
obstructs metastasis without confound-
ing influences on primary tumor develop-
ment andmay, thus, be a true ‘‘metastasis
suppressor gene,’’ as the authors sug-
gested.
Furthermore, by identifying a cohort of
prometastatic genes regulated by miR-
31, the authors also provide new insights
into the mechanisms underlying meta-
static spread. The coordinate repression
of six of these genes, frizzled3 (Fzd3),
integrin a5 (ITGA5), myosin phosphatase-
Rho interacting protein (M-RIP), matrix
metalloproteinase 16 (MMP16), radixin
(RDX), and RhoA, correlated with more
favorable clinical outcome in breast
cancers and may, thus, have prognostic
value. Notably, complete repression was
not necessary to obtain functional effects.
In addition, re-expression of three of
these genes, ITGA5, RDX, or RhoA, in
metastatic breast cancer cells reversed
the impaired motility, invasion, and resis-
tance to anoikis conferred by miR-31
(Figure 1). These data indicate that these
genes are functionally relevant targets ofREFERENCES
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